The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Yasuhiro Oki; Hubert Chuang; Beth Chasen; Aaron Jessop; Tinsu Pan; Michelle Fanale; Bouthaina Dabaja; Nathan Fowler; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Maria Alma Rodriguez; Sattva Neelapu; Felipe Samaniego; Larry Kwak; Anas Younes

doi:10.1111/bjh.12715

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Yasuhiro Oki, Hubert Chuang, Beth Chasen, Aaron Jessop, Tinsu Pan, Michelle Fanale, Bouthaina Dabaja, Nathan Fowler, Jorge Romaguera, Luis Fayad, Fredrick Hagemeister, Maria Alma Rodriguez, Sattva Neelapu, Felipe Samaniego, Larry Kwak, Anas Younes

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.

Original language	English (US)
Pages (from-to)	112-116
Number of pages	5
Journal	British Journal of Haematology
Volume	165
Issue number	1
DOIs	https://doi.org/10.1111/bjh.12715
State	Published - Apr 2014

Keywords

Hodgkin lymphoma
Positron emission tomography
Prognostic

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1111/bjh.12715

Cite this

Oki, Y., Chuang, H., Chasen, B., Jessop, A., Pan, T., Fanale, M., Dabaja, B., Fowler, N., Romaguera, J., Fayad, L., Hagemeister, F., Rodriguez, M. A., Neelapu, S., Samaniego, F., Kwak, L., & Younes, A. (2014). The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology, 165(1), 112-116. https://doi.org/10.1111/bjh.12715

Oki, Y, Chuang, H , Chasen, B , Jessop, A , Pan, T, Fanale, M, Dabaja, B, Fowler, N, Romaguera, J, Fayad, L, Hagemeister, F, Rodriguez, MA, Neelapu, S , Samaniego, F, Kwak, L & Younes, A 2014, 'The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma', British Journal of Haematology, vol. 165, no. 1, pp. 112-116. https://doi.org/10.1111/bjh.12715

@article{319e312aaafe45fabb0df1223dd47f8a,

title = "The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma",

abstract = "The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.",

keywords = "Hodgkin lymphoma, Positron emission tomography, Prognostic",

author = "Yasuhiro Oki and Hubert Chuang and Beth Chasen and Aaron Jessop and Tinsu Pan and Michelle Fanale and Bouthaina Dabaja and Nathan Fowler and Jorge Romaguera and Luis Fayad and Fredrick Hagemeister and Rodriguez, {Maria Alma} and Sattva Neelapu and Felipe Samaniego and Larry Kwak and Anas Younes",

year = "2014",

month = apr,

doi = "10.1111/bjh.12715",

language = "English (US)",

volume = "165",

pages = "112--116",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

AU - Oki, Yasuhiro

AU - Chuang, Hubert

AU - Chasen, Beth

AU - Jessop, Aaron

AU - Pan, Tinsu

AU - Fanale, Michelle

AU - Dabaja, Bouthaina

AU - Fowler, Nathan

AU - Romaguera, Jorge

AU - Fayad, Luis

AU - Hagemeister, Fredrick

AU - Rodriguez, Maria Alma

AU - Neelapu, Sattva

AU - Samaniego, Felipe

AU - Kwak, Larry

AU - Younes, Anas

PY - 2014/4

Y1 - 2014/4

N2 - The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.

AB - The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.

KW - Hodgkin lymphoma

KW - Positron emission tomography

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=84896042967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896042967&partnerID=8YFLogxK

U2 - 10.1111/bjh.12715

DO - 10.1111/bjh.12715

M3 - Article

C2 - 24386943

AN - SCOPUS:84896042967

SN - 0007-1048

VL - 165

SP - 112

EP - 116

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this